A faster treat­ment for tu­ber­cu­lo­sis? TB Al­liance launch­es piv­otal tri­al for four-drug reg­i­men

Com­bin­ing some of the lat­est break­throughs in tu­ber­cu­lo­sis re­search with some of the old­est treat­ment op­tions, the TB Al­liance has launched a piv­otal tri­al to test how well their four-drug reg­i­men can treat tu­ber­cu­lo­sis in light of grow­ing re­sis­tance to cur­rent ther­a­pies.

The not-for-prof­it is con­tribut­ing an ex­per­i­men­tal com­pound, pre­tomanid, which rep­re­sents a class of nov­el an­ti-bac­te­r­i­al agents called ni­troim­i­da­zole. The rest of the reg­i­men calls for J&J’s be­daquiline — per­haps bet­ter known as Sir­turo — the off-patent an­tibi­ot­ic mox­i­floxacin, and pyraz­i­namide, a gener­ic med of­ten found in TB com­bos.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER